81 related articles for article (PubMed ID: 15866669)
1. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center.
Campos A; Lage E; Hinojosa R; Ordóñez A; Cisneros JM; Cabezón S; Gómez S; Aguilera A; Arana E; Cayuela A
Transplant Proc; 2005 Apr; 37(3):1548-9. PubMed ID: 15866669
[TBL] [Abstract][Full Text] [Related]
2. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
[TBL] [Abstract][Full Text] [Related]
3. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
6. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH
Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
[TBL] [Abstract][Full Text] [Related]
8. Influence of induction therapy on rejection and survival in heart transplantation.
Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-alpha therapy for acute rejection in intestinal transplantation.
Pascher A; Klupp J; Langrehr JM; Neuhaus P
Transplant Proc; 2005 Apr; 37(3):1635-6. PubMed ID: 15866693
[TBL] [Abstract][Full Text] [Related]
10. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
11. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
12. Is it possible to reduce the number of endomyocardial biopsies with new immunosuppressive drugs?
Lage E; Ballesteros S; Mogollón MV; Ordóñez A; Gómez S; Hernández A; Hinojosa R
Transplant Proc; 2006 Oct; 38(8):2544-6. PubMed ID: 17097996
[TBL] [Abstract][Full Text] [Related]
13. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
Lácha J; Símová M; Nosková L; Teplan V; Vítko S
Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
[No Abstract] [Full Text] [Related]
14. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
Schulz T; Flecken M; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
[TBL] [Abstract][Full Text] [Related]
15. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy with daclizumab in heart transplantation--how many doses?
Ortiz V; Almenar L; Martínez-Dolz L; Zorio E; Chamorro C; Moro J; Agüero J; Rueda J; Arnau MA; Salvador A
Transplant Proc; 2006 Oct; 38(8):2541-3. PubMed ID: 17097995
[TBL] [Abstract][Full Text] [Related]
17. [Individual immunosuppressive regime in heart transplantation with high risk].
Wu XJ; Chen LW; Chen DZ; Huang XS; Cao H
Zhonghua Wai Ke Za Zhi; 2008 Jun; 46(11):820-2. PubMed ID: 19035214
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation.
Mullen JC; Oreopoulos A; Lien DC; Bentley MJ; Modry DL; Stewart K; Winton TL; Jackson K; Doucette K; Preiksaitis J; Halloran PF
J Heart Lung Transplant; 2007 May; 26(5):504-10. PubMed ID: 17449421
[TBL] [Abstract][Full Text] [Related]
19. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
20. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
